The Indian Rupee (INR) touched an all-time low of 69.80 against the US dollar (USD) on Monday (13) following a weak trend in the currencies of developing countries.
Following a high volatility in the currency market, India’s central bank, Reserve Bank of India (RBI) was seen intervening the market. However, RBI’s intervention was mild and it was intended to limit the higher volatility in the early trade. INR has recorded a fall over 7.5 per cent so far in 2018. INR had closed at 68.84 against USD on last Friday (10).
Investors preferred safe havens such as the USD and the Japanese Yen after a plunge in the Turkish currency lira forced all the developing countries currencies to remain weak. The lira has tumbled about 45 per cent against USD in 2018 following concerns over Turkish President’s increasing grip over the domestic economy and thickening diplomatic issues with the United States.
Turkey’s central bank on Monday (13) said it was ready to take all possible measures to prevent fall of lira to ensure the financial stability of the country. The statement from the central bank came after the Turkish lira recorded a steep decline against USD.
Investors were seen waiting for India consumer inflation data for July which is expected after market hours for further direction. On Monday, India’s NSE Nifty 50 closed at 11,355.75 points, lower by 73.75 points or 0.65 per cent from its previous close whereas, BSE Sensex, closed at 37,644.90 down by 224.33 points or 0.59 per cent. The top gainers on BSE were, Infosys, Sun Pharma, Wipro, Mahindra and Mahindra and Coal India, while the top losers were Yes Bank, Vedanta, Tata Motors (DVR), SBI, and ONGC.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.